SecBot SecBot
8-K ·Filed Jul 31, 2026

MRNA

Moderna, Inc.
MIXED
Impact 6/10
Horizondays Processed3mo ago SEC0001682852-26-000147
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

The norovirus Phase 3 failure is a material pipeline setback that will likely dominate the narrative and pressure the stock near-term, despite the modest financial beat. Watch for the August 5 PDUFA decision on mFLUSIVA as a potential offsetting catalyst. The improved cash guidance provides some downside protection, but the pipeline read-through is negative.

DirectionMixed
Confidencehigh
Horizondays

Drugs in focus

MRNA drug pipeline →

mRNA-1010

▲ Bullish Named in this 8-K
Impact
Phase
Filed / PDUFA (Phase 3 completed)
Time to market
PDUFA date is August 5, 2026. If approved, the vaccine could be available for the 2026/2027 Northern Hemisphere flu season. Regulatory submissions are also under review in Europe, Canada, and Australia, with potential approvals expected in 2026.
Next catalyst
None dated

What to watchWatch for the FDA decision by August 5, 2026. The unanimous 9-0 advisory committee vote on June 18 makes approval the base case, and the stock has already re-rated from a 52-week low of $22 to ~$71 on the expectation, so a positive decision may be partially priced in. Approval would unlock a new multi-billion-dollar TAM for Moderna beyond COVID; a surprise CRL would be a severe setback for the stock given how much of the 2026 rally is built on flu vaccine hopes.

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$54.82
T+0 close · Jul 31, 2026 · via day close
Latest settled
+262.73%
T+60 · $198.85
Vs SPY
+260.28%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 31 $54.82entry
  2. T+1 · 4mo ago +0.48%α −0.93% · $55.08
  3. T+5 · 3mo ago +7.94%α +4.42% · $59.17
  4. T+20 · 3mo ago +151.71%α +148.73% · $137.99
  5. T+60 · 22d ago +262.73%α +260.28% · $198.85
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Moderna reported Q2 2026 revenue of $145M (vs $103.9M consensus) and GAAP EPS of -$1.97 (vs -$2.06 consensus), a modest beat on both lines. The company reiterated its plan for up to 10% revenue growth in 2026 and improved its operating expense and year-end cash guidance. However, the norovirus vaccine candidate mRNA-1403 failed a Phase 3 interim analysis, a significant pipeline setback that will likely overshadow the financial beat and weigh on sentiment.

Key Financial Metrics

EPS
−$1.97
est −$2.06 · +4.4%
Revenue
$145.0M
est $103.9M · +39.6% · +2.1% YoY
Rating
in line
Guidance
up to 10% growth from 2025 revenue
maintained
Free Cash Flow
-$1.3B
Gross Margin
35.86%

Key Facts

  • Q2 2026 revenue of $145M, up 2% YoY from $142M, beating consensus of $103.9M.
  • GAAP EPS of -$1.97, beating consensus of -$2.06 by 4.4%.
  • Norovirus vaccine candidate mRNA-1403 failed Phase 3 interim analysis; trial ongoing with additional cohort enrollment.
  • 2026 R&D expense guidance lowered to ~$2.9B from ~$3.0B; year-end cash guidance improved to $4.7-5.2B.
  • mFLUSIVA (seasonal flu vaccine) has a PDUFA date of August 5, 2026, with potential to become the fifth approved product.
  • Cash, cash equivalents and investments at $6.9B as of June 30, 2026, down from $7.5B at March 31, 2026.

Financial Impact

Revenue beat of ~$41M vs consensus; EPS beat of $0.09 vs consensus. Norovirus pipeline failure removes a key growth catalyst.

revenueepspipeline value

Risk Factors

  • Norovirus vaccine failure removes a key pipeline catalyst and raises questions about the broader vaccine platform's success rate.
  • Revenue growth remains heavily dependent on COVID vaccine sales, which are declining year-over-year.
  • The company has a history of high cash burn; the improved guidance still implies significant cash consumption.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
13% bullish (30 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001682852-26-000147
Document: mrna-20260731.htm0001682852-26-000147
Document: 0001682852-26-000147-index-headers.html0001682852-26-000147
Document: 0001682852-26-000147-index.html0001682852-26-000147
Document: 0001682852-26-000147.txt0001682852-26-000147
8-K Data (Synthetic)0001682852-26-000147

Track record

26 reports on MRNA

Performance horizon

6 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +14.15% at T+60 after the Mar 5, 2026 report. 7 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today 144 Neutral 3/10 Entry $217.29 Now $215.27 −0.93% settles Nov 17
  2. Nov 13, 20263d ago 8-K Neutral 3/10 Entry $222.50 Now $215.27 −3.25% settles Nov 17
  3. Nov 6, 202610d ago 8-K Bullish 7/10 Entry $254.19 to $269.00 Now $215.27 −15.31% ▲ +5.83% +3.46% vs SPY
  4. Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $241.46 to $254.19 Now $215.27 −10.85% ▲ +5.27% +4.96% vs SPY
  5. Oct 28, 202619d ago Institutional Cluster Neutral 3/10 Entry $214.17 to $222.76 Now $215.27 +0.52% ▲ +4.01% +4.40% vs SPY
  6. Oct 27, 202620d ago ANALYST-DOWNGRADE Bearish 4/10 Entry $207.97 to $214.17 Now $215.27 −3.51% ▼ −2.98% −2.63% vs SPY
  7. Sep 30, 20266w ago 8-K Neutral 3/10 Entry $192.57 to $188.94 Now $215.27 +11.79% ▼ −1.89% −2.06% vs SPY
  8. Sep 30, 20266w ago ANALYST-DOWNGRADE Bearish 4/10 No price data
  9. Sep 16, 20268w ago Insider Cluster Bearish 5/10 Entry $158.07 to $154.04 Now $215.27 −36.19% ▲ +2.55% +2.43% vs SPY
  10. Sep 3, 202610w ago ANALYST-DOWNGRADE Bearish 6/10 Entry $148.87 to $145.55 Now $215.27 −44.60% ▲ +2.23% +1.84% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens in 6h 23m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 31, 2026